TrialThe Journal of infectious diseases2015

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.

Anne Schuind et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.